Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$1.15 AUD
Change Today -0.02 / -1.71%
Volume 1.3M
As of 2:10 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

impedimed ltd (IPD) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - A$1.20
52 Week Low
08/11/14 - A$0.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMPEDIMED LTD (IPD)

Related News

No related news articles were found.

impedimed ltd (IPD) Related Businessweek News

No Related Businessweek News Found

impedimed ltd (IPD) Details

ImpediMed Limited develops, manufactures, and sells bioimpedance and bioimpedance spectroscopy devices, and consumables for clinicians and allied health professionals in Australia, Canada, Mexico, The United States, and internationally. The company operates through Medical, and Test & Measurement segments. The Medical segment offers non-invasive medical devices for the assessment and monitoring of secondary lymphoedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring, and sports medicine and fitness, as well as body composition and hydration. The Test & Measurement segment supplies power precision testing and measuring equipment. The company offers its products through distributors. ImpediMed Limited was founded in 1999 and is based in Pinkenba, Australia.

40 Employees
Last Reported Date: 02/25/15
Founded in 1999

impedimed ltd (IPD) Top Compensated Officers

Chief Executive Officer, President and Managi...
Total Annual Compensation: A$571.1K
Chief Financial Officer
Total Annual Compensation: A$282.2K
Vice President of Global Commercialization
Total Annual Compensation: A$313.4K
Vice President of Product Development, Qualit...
Total Annual Compensation: A$267.7K
Vice President of Regulatory, Clinical Affair...
Total Annual Compensation: A$267.7K
Compensation as of Fiscal Year 2014.

impedimed ltd (IPD) Key Developments

ImpediMed Limited Appoints Richard Carreon as Managing Director

ImpediMed Limited announced the appointment of Mr. Richard Carreon as Managing Director of the company effective 9 May 2015. Mr. Carreon is currently the Chief Executive Officer of the Company.

ImpediMed Limited(ASX:IPD) added to S&P/ASX 300 Index

ImpediMed Limited(ASX:IPD) added to S&P/ASX 300 Index

ImpediMed Limited(ASX:IPD) added to S&P/ASX All Ordinaries Index

ImpediMed Limited(ASX:IPD) added to S&P/ASX All Ordinaries Index


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPD:AU A$1.15 AUD -0.02

IPD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPD.
View Industry Companies

Industry Analysis


Industry Average

Valuation IPD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.4x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 65.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPEDIMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at